{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-26-000053","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.015061+00:00","generated_at":"2026-05-15T00:33:19.157929+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Halozyme names Darren Snellgrove as CFO, effective June 8, 2026","bullets":["Darren Snellgrove appointed CFO effective June 8, 2026; previously VP IR at Johnson & Johnson and CFO of its Pharmaceuticals sector.","Compensation: $670,000 annual salary, 50% bonus target, $350,000 sign-on cash bonus, and $7.2M new-hire equity awards ($3.2M RSUs + $4M options).","2027 long-term incentive minimum $4M; make-whole RSUs vest over 3 years, stock options vest 25% after 1 year then monthly.","David Ramsay, interim CFO, will assume advisory role effective June 8, 2026 to assist transition.","Snellgrove holds MBA from Villanova, BA from University of Southampton; no family relationships or material interests in transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-26-000053","json":"https://secwatch.observer/filing/0001159036-26-000053.json","markdown":"https://secwatch.observer/filing/0001159036-26-000053.md","text":"https://secwatch.observer/filing/0001159036-26-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/0001159036-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/halo-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:33:19.157929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d5a33948e","claim":"David Ramsay changed role as Interim CFO at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"Effective as of June 8, 2026, David Ramsay, the Company’s current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/0001159036-26-000053-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"will assume an advisory role"},{"label":"Role","value":"Interim CFO"}],"fact_type":"executive_change"},{"claim_id":"8b0dab755f","claim":"Darren Snellgrove was appointed as Chief Financial Officer at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/0001159036-26-000053-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}